Healthcare Industry News: Dermal Filler
News Release - January 7, 2009
Q-Med has obtained registration approval for Restylane(R) in ChinaSTOCKHOLM, Sweden, Jan 7, 2009 - (HSMN NewsFeed) - Q-Med has obtained registration approval for Restylane(R) in China. An application for sales approval will be submitted shortly and it is estimated that sales of the product will begin at the end of the second quarter in 2009.
"There is a large appetite for new things in China and great respect for products from the West. We are therefore very pleased about this registration approval, which means that Restylane(R) will be the first hyaluronic acid product intended for the cosmetic market in China", says Bengt Ågerup, Q-Med's President and CEO.
Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane(R) for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux(R) for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta(TM) for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.
Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: email@example.com. Web: www.q-med.com.
In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.